Screener
CRISPR Therapeutics CRSP Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $13,647 | $11,138 |
| Accrued expenses | 74,932 | 89,407 |
| Deferred revenue, current | 15,344 | 15,771 |
| Accrued tax liabilities | 638 | 1,113 |
| Operating lease liabilities | 18,612 | 18,578 |
| Other current liabilities | 13,113 | 13,113 |
| Total current liabilities | 136,286 | 149,120 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's deferred revenue?
- CRISPR Therapeutics (CRSP) reported deferred revenue of $15.34M in Q1 2026.
- How has CRISPR Therapeutics's deferred revenue changed year-over-year?
- CRISPR Therapeutics's deferred revenue increased by 407.9% year-over-year, from $3.02M to $15.34M.
- What is the long-term trend for CRISPR Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's deferred revenue has grown at a 46.5% compound annual growth rate (CAGR), from $2.34M to $15.77M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about CRISPR Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude